Altimmune's Milestone Achievement in Obesity Treatment
Company and FDA have reached consensus on important efficacy and safety metrics for the upcoming Phase 3 trial.
Overview of the Meeting with FDA
Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company in the clinical stage, confirmed the successful conclusion of its End-of-Phase 2 Meeting with the Food and Drug Administration (FDA). This meeting allowed them to outline a prospective Phase 3 program for pemvidutide, an innovative treatment aimed at addressing obesity.
Vipin K. Garg, Ph.D., the Chief Executive Officer of Altimmune, expressed gratitude for the productive discussions with the FDA. He emphasized the importance of focusing on therapies that tackle obesity and its associated conditions. As the drug development landscape evolves, securing this agreement is essential, especially as the company gears up for new partnerships and the anticipated data from their Phase 2b study.
Insights into the Phase 3 Trial Design
The collaboration with the FDA involved a thorough examination of existing preclinical and clinical data, which included six trials revolving around pemvidutide. The upcoming Phase 3 program is set to encompass four key trials, each designed as randomized, double-blind, placebo-controlled studies. These trials aim to evaluate the effects of pemvidutide over the course of 60 weeks and are projected to enlist around 5,000 participants.
Each of the trials will investigate the safety and efficacy of three different doses of pemvidutide: 1.2 mg, 1.8 mg, and 2.4 mg, with the goal of achieving regulatory approval for each dosage. Highlights of the trial designs include:
VELOCITY-1 Trial
This study will focus on the impact of pemvidutide on weight management among individuals suffering from obesity or being overweight, without diabetes. The trial will also track changes in waist size, blood pressure, and serum lipid levels.
VELOCITY-2 Trial
This trial's scope will explore pemvidutide's effect on body weight and lipid levels in individuals with obesity and high LDL cholesterol. Notably, the study will include patients who have not achieved cholesterol targets while on statins, examining pemvidutide's potential to enhance LDL reduction.
VELOCITY-3 Trial
Participants in this trial will be those dealing with obesity and elevated liver fat. The presence of excess liver fat is common among obese patients and is linked to heightened cardiovascular risks.
VELOCITY-4 Trial
This trial will assess the effect of pemvidutide on both body weight and composition in older adults, particularly those who exhibit sarcopenia. Functional performance and daily living activities will be key focus areas in this demographic.
Benefits of Pemvidutide in Obesity Management
Scott Harris, M.D., Chief Medical Officer at Altimmune, underscored the significance of the favorable results from the recent FDA meeting. He highlighted pemvidutide's unique characteristics compared to existing treatments, emphasizing its potential not just for weight loss but also for improving lipid profiles, reducing liver fat, and preserving lean body mass.
Understanding Pemvidutide
Pemvidutide is an investigational, peptide-based dual receptor agonist that targets both GLP-1 and glucagon receptors. This mechanism is expected to replicate the favorable effects of a healthy diet and exercise by suppressing appetite and boosting energy expenditure. Research has shown that pemvidutide effectively reduces body weight while preserving muscle mass and lowering triglycerides and LDL cholesterol levels.
Furthermore, the FDA has acknowledged pemvidutide's potential, granting it Fast Track designation for the treatment of metabolic dysfunctions linked to obesity. Recent trials, including the MOMENTUM Phase 2 obesity study, have showcased pemvidutide's efficacy, and Altimmune is actively progressing with the IMPACT Phase 2b study.
About Altimmune
Altimmune is committed to developing pioneering peptide-based therapeutics to address significant health challenges. With a primary focus on pemvidutide, the company is leading efforts for innovative treatments aimed at obesity and metabolic syndromes. For insights on their work, visit www.altimmune.com.
Frequently Asked Questions
What is pemvidutide?
Pemvidutide is a novel investigational treatment targeting obesity through dual receptor agonism of GLP-1 and glucagon to manage weight effectively.
What were the outcomes of the FDA meeting?
Altimmune successfully aligned with the FDA on the design of a Phase 3 program for pemvidutide, marking a significant regulatory milestone.
How many trials are included in the Phase 3 program?
The Phase 3 program will consist of four pivotal trials, focusing on different aspects of weight management and associated health conditions.
What are the benefits of pemvidutide compared to other treatments?
Pemvidutide is believed to offer unique advantages, including significant weight loss, lipid level improvement, and preservation of muscle mass.
Who is Altimmune?
Altimmune is a biopharmaceutical company dedicated to developing innovative therapeutics, actively working on treatments for obesity and metabolic health.
